公开(公告)号：EP3630283A1

公开(公告)日：2020-04-08

申请号：EP18810795.7

申请日：2018-05-31

申请人： Immunolight, LLC ,  Duke University

发明人： BOURKE, Frederic A. ,  DEWHIRST, Mark ,  SPECTOR, Neil ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya ,  OLDHAM, Mark ,  FATHI, Zakaryae ,  BEYER, Wayne F. ,  WALDER, Harold

IPC分类号： A61N5/06 ,  A61B6/00 ,  A61K9/00 ,  A61K49/04 ,  A61N5/10

公开(公告)号：EP2788004A1

公开(公告)日：2014-10-15

申请号：EP12861144.9

申请日：2012-12-07

申请人： Duke University

发明人： KORNBLUTH, Sally ,  KUROKAWA, Manabu ,  SPECTOR, Neil ,  DEWHIRST, Mark

IPC分类号： A61K31/675 ,  A61K31/40 ,  A61K39/395 ,  G01N33/53

CPC分类号： A61K31/517 ,  A61K31/404 ,  A61K31/407 ,  A61K31/496 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/32 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y603/02 ,  G01N33/5011 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

公开(公告)号：EP2788004B1

公开(公告)日：2019-07-03

申请号：EP12861144.9

申请日：2012-12-07

申请人： Duke University

发明人： KORNBLUTH, Sally ,  KUROKAWA, Manabu ,  SPECTOR, Neil ,  DEWHIRST, Mark

IPC分类号： A61K31/496 ,  A61K39/395 ,  G01N33/53 ,  A61K31/517 ,  A61K31/407 ,  A61P35/00 ,  G01N33/50 ,  C12N15/113 ,  C07K16/32 ,  A61K45/06